Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

(2013) Y. Feng et al.   CLINICAL CANCER RESEARCH

A Guide to Rational Dosing of Monoclonal Antibodies

(2012) Shuang Bai et al.   CLINICAL PHARMACOKINETICS

Fundamentals of Population Pharmacokinetic Modelling

(2012) Catherine M. T. Sherwin et al.   CLINICAL PHARMACOKINETICS

Rivaroxaban

(2011) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Essential Pharmacokinetic Information for Drug Dosage Decisions: A Concise Visual Presentation in the Drug Label

(2011) D Menon-Andersen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2b

(2011) Matthew M. Riggs et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

Population Pharmacokinetics of Tapentadol Immediate Release (IR) in Healthy Subjects and Patients with Moderate or Severe Pain

(2010) Xu Steven Xu et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2010) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

(2010) Axel Hoos et al.   SEMINARS IN ONCOLOGY

Population pharmacokinetic analysis of varenicline in adult smokers

(2009) Patanjali Ravva et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

(2009) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?

(2008) Barrett W. Newsome et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

(2008) Lawrence Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

(2008) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS